Autogenic Inhibition Versus Reciprocal Inhibition Muscle Energy Techniques in Iliotibial Band Syndrome

NCT ID: NCT06867159

Last Updated: 2025-03-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-15

Study Completion Date

2025-07-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Comparison of effects of autogenic inhibition and reciprocal inhibition muscle energy techniques on iliotibial band syndrome

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A single-blinded randomized control trial will be conducted over a period of one year in Foundation University Islamabad. Forty participants will be assigned to two groups: Group A (AI) and Group B (RI), with 20 participants each. The AI technique will involve a maximal isometric contraction of the target muscle followed by a stretch, while the RI technique will involve a maximal isometric contraction of the antagonist muscle followed by a similar stretching protocol. Both groups will perform the exercises 3 times per week for 2 weeks. Pain, Hip range of motion (ROM) and lower extremity function will be assessed using Numeric Pain Rating Scale (NPRS), goniometer and Lower Extremity Functional Scale (LEFS) respectively.

The outcomes will be measured in terms of improvements in pain score (NPRS), hip range of motion (ROM), and overall lower extremity function.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Iliotibial Band Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized Controlled Trial
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors
It will be a single blinded RCT in which assessor will be blinded to the group allocation of participants.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Autogenic Inhibition (AI) MET Group

Autogenic Inhibition (AI) MET (Post Facilitation Stretch)

1. The shortened muscle (Tensor Fascia Latae) is placed in a mid-range position about halfway between a fully stretched and a fully relaxed state.
2. The patient contracts the muscle isometrically, using a maximum degree of effort for 5-10 seconds while the effort is resisted completely.
3. On release of the effort, a rapid stretch is made to a new barrier, without any 'bounce', and this is held for at least 10 seconds.
4. The patient relaxes for approximately 20 seconds and the procedure is repeated between three and five times more.

Group Type EXPERIMENTAL

Autogenic Inhibition (AI) MET (Post Facilitation Stretch)

Intervention Type PROCEDURE

Autogenic Inhibition (AI) MET (Post Facilitation Stretch)

1. The shortened muscle (Tensor Fascia Latae) is placed in a mid-range position about halfway between a fully stretched and a fully relaxed state.
2. The patient contracts the muscle isometrically, using a maximum degree of effort for 5-10 seconds while the effort is resisted completely.
3. On release of the effort, a rapid stretch is made to a new barrier, without any 'bounce', and this is held for at least 10 seconds.
4. The patient relaxes for approximately 20 seconds and the procedure is repeated between three and five times more.

Reciprocal Inhibition (RI) MET Group

Reciprocal Inhibition (RI) MET

1. The shortened muscle (Tensor Fascia Latae) is placed in a mid-range position about halfway between a fully stretched and a fully relaxed state.
2. The patient contracts the antagonist muscles (hip adductors), using a maximum degree of effort for 5-10 seconds while the effort is resisted completely.
3. On release of the effort, a rapid stretch to TFL is made to a new barrier, without any 'bounce', and this is held for at least 10 seconds.
4. The patient relaxes for approximately 20 seconds and the procedure is repeated between three and five times more.

Group Type EXPERIMENTAL

Reciprocal Inhibition (RI) MET

Intervention Type PROCEDURE

Reciprocal Inhibition (RI) MET

1. The shortened muscle (Tensor Fascia Latae) is placed in a mid-range position about halfway between a fully stretched and a fully relaxed state.
2. The patient contracts the antagonist muscles (hip adductors), using a maximum degree of effort for 5-10 seconds while the effort is resisted completely.
3. On release of the effort, a rapid stretch to TFL is made to a new barrier, without any 'bounce', and this is held for at least 10 seconds.
4. The patient relaxes for approximately 20 seconds and the procedure is repeated between three and five times more.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Autogenic Inhibition (AI) MET (Post Facilitation Stretch)

Autogenic Inhibition (AI) MET (Post Facilitation Stretch)

1. The shortened muscle (Tensor Fascia Latae) is placed in a mid-range position about halfway between a fully stretched and a fully relaxed state.
2. The patient contracts the muscle isometrically, using a maximum degree of effort for 5-10 seconds while the effort is resisted completely.
3. On release of the effort, a rapid stretch is made to a new barrier, without any 'bounce', and this is held for at least 10 seconds.
4. The patient relaxes for approximately 20 seconds and the procedure is repeated between three and five times more.

Intervention Type PROCEDURE

Reciprocal Inhibition (RI) MET

Reciprocal Inhibition (RI) MET

1. The shortened muscle (Tensor Fascia Latae) is placed in a mid-range position about halfway between a fully stretched and a fully relaxed state.
2. The patient contracts the antagonist muscles (hip adductors), using a maximum degree of effort for 5-10 seconds while the effort is resisted completely.
3. On release of the effort, a rapid stretch to TFL is made to a new barrier, without any 'bounce', and this is held for at least 10 seconds.
4. The patient relaxes for approximately 20 seconds and the procedure is repeated between three and five times more.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Both male and female participants
* Age : 19-45years (8)
* Lateral knee pain (\>3 months)
* Tenderness over lateral femoral condyle
* Positive Flexibility Tests
* Modified Ober's test (9)
* Length assessment of Tensor Fasciae Latae and Iliotibial Band (10)
* Positive Pain Provocation Tests
* Renne's test
* Noble's Compression test (11) \*(individuals with 3 positive tests out of above mentioned 4 tests will be included)

Exclusion Criteria

* Recent lower limb or pelvic girdle surgery within the past 3 months
* Lower limb fractures or trauma within the past year.
* Multiple lower limb surgeries (\>2)
* Presence of any structural or postural disorders (kyphosis or severe scoliosis)
* Neurological disorders
* Hip and knee Osteoarthritis
* Rheumatoid Arthritis
* Pregnancy
Minimum Eligible Age

19 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Foundation University Islamabad

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Foundation University College of Physcial Therapy

Rawalpindi, Punjab Province, Pakistan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Pakistan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Rida Ishtiaq, MS-MSKPT*

Role: CONTACT

03365530415

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Furqan Yaqoob, OMPT,PHD*

Role: primary

03465333101

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FUI/CTR/2025/3

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.